Yaofang Biotech

Yaofang Biotech is an innovative biopharmaceutical company based in Shanghai, China, specializing in the development of next-generation therapeutics using Targeted Protein Degradation (TPD) technology. The company leverages its proprietary PROTAC (Proteolysis-Targeting Chimera) platform to design small molecules that degrade previously "undruggable" proteins involved in cancer and immunological disorders. Its lead candidate, YF-01, is a potent and selective STAT3 degrader that has received IND clearance from the US FDA for the treatment of advanced solid tumors and hematological malignancies. Founded in 2021 by veterans of the global pharmaceutical industry, Yaofang Biotech has rapidly advanced its pipeline and secured significant funding from top-tier venture capital firms such as IDG Capital and Gaorong Capital. The company aims to provide transformative treatments for patients with high unmet medical needs by addressing complex signaling pathways through efficient protein turnover.